CAMBRIDGE, Mass., June 1 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the appointment of
three members to the executive management team. Effective immediately,
Chief Scientific Officer Joseph Bolen, Ph.D., Chief Medical Officer Nancy
Simonian, M.D., and Senior Vice President of Non-Clinical Development
Sciences Peter Smith, Ph.D., will lead the Company's research and
development efforts and join the executive management team.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"The skill, experience and passion that Joe, Nancy and Pete bring to
their jobs are unequaled in the industry. Together, they will continue to
drive our efforts of bringing new medicines to patients," says Deborah
Dunsire, M.D., President and CEO of Millennium.
Collectively, Drs. Bolen, Simonian and Smith possess more than 60 years
of drug development experience:
-- Joe Bolen (Boston, Mass.) joined Millennium in 1999 to lead the
Company's oncology discovery efforts. In 2002 he was appointed Senior
Vice President of Discovery, and named Chief Scientific Officer in
2006. Prior to joining Millennium, Joe held positions with Hoechst
Marion Roussel, DNAX Research Institute of Molecular and Cellular
Biology, Bristol-Myers Squibb Pharmaceutical Research Institute and the
National Institutes of Health.
-- Nancy Simonian (Wayland, Mass.) joined Millennium in 2001 to lead the
Company's clinical development efforts, and in 2006 was named Chief
Medical Officer. She is responsible for all clinical, regulatory,
pharmacovigilance and development project management functions at the
Company. Prior to joining Millennium, she held a clinical research
position at Biogen. Board-certified in neurology, Nancy was previously
an assistant clinical professor of neurology at Massachusetts General
Hospital and Harvard Medical School.
-- Peter Smith (Norwell, Mass.) joined Millennium in 2001 as Senior Vice
President of Preclinical Development and was named Senior Vice
President of Non-Clinical Development Sciences in 2006. In this role,
he oversees preclinical development for all discovery and development
programs. Prior to joining Millennium, Peter held positions at
Smithkline, Merck, Pharmacia and Searle/Monsanto.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a
novel cancer product, and has a robust clinical development pipeline of
product candidates. The Company's research, development and
commercialization activities are focused in two therapeutic areas: oncology
and inflammation. By applying its knowledge of the human genome,
understanding of disease mechanisms and industrialized drug discovery
platform, Millennium is
developing an exciting pipeline of innovative product candidates. The
Company's website is http://www.millennium.com.
This press release contains "forward-looking statements," including
statements about the Company's growth. Various important risks may cause
the Company's actual results to differ materially from the results
indicated by these forward-looking statements, including: adverse results
in its drug discovery and clinical development programs; failure to obtain
patent protection for its discoveries; commercial limitations imposed by
patents owned or controlled by third parties; the Company's dependence upon
strategic alliance partners to develop and commercialize products and
services based on its work; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from its development
efforts; product withdrawals; competitive factors; difficulties or delays
in manufacturing the Company's products; government and third-party
reimbursement rates; the commercial success of VELCADE(R) (bortezomib) for
Injection and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue
consistent with internal forecasts; and the requirement for substantial
funding to conduct research and development and to expand commercialization
activities. For a further list and description of the risks and
uncertainties the Company faces, see the reports it has filed with the
Securities and Exchange Commission. The Company disclaims any intention or
obligation to update or revise any forward- looking statements, whether as
a result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
Contacts:
Jennifer Snyder (media) Kyle Kuvalanka (investors)
(617) 444-1439 (617) 761-4734
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html/
CONTACT:
Media, Jennifer Snyder, +1-617-444-1439, or
Investors, Kyle Kuvalanka, +1-617-761-4734, both of Millennium
Pharmaceuticals, Inc.
|
